stockrow
Friday 6 November 2026
Export SY’s income statement to Excel — free account
So-Young International Inc. Sponsored ADR
SY Healthcare Health Information Services
So-Young International Inc. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $217.8 million, up 8.41% from fiscal 2024.
- Revenue
- +40.8%
- EPS
- +40.0%
- Free cash flow
- −798.4%
- Total debt
- +99.7%
Quarter to June 2026, against a year earlier
2.06
0.03
−1.44%
Follow SY
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
0.57 | 1.15 | 1.19 | 1.99 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 | |
P/B ratio |
0.64 | 1.18 | 1.09 | 1.55 | |
Price to Tangible BV |
0.70 | 1.30 | 1.19 | 1.67 | |
EV/Sales |
0.16 | 0.69 | 0.60 | 1.34 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.30) | (5.21) | (4.12) | (75.60) | |
EV/FCF |
(0.53) | (2.13) | (1.68) | (9.22) | |
Quick Ratio |
1.01 | 1.10 | 1.28 | 1.54 | |
Current Ratio |
1.61 | 1.73 | 1.89 | 2.20 | |
Net Debt/EBITDA |
16.85 | 13.13 | 7.06 | 12.42 | |
Debt/Assets |
4.22% | 4.49% | 1.50% | 1.51% | |
Debt/Equity |
0.07 | 0.07 | 0.02 | 0.02 | |
Asset Turnover |
0.68 | 0.64 | 0.58 | 0.47 | |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
— | — | (3.44) | — | |
Research and Development Expense of Revenue |
4.83% | 5.62% | 8.20% | 9.39% | |
Selling, General and Administrative Expense of Revenue |
47.92% | 49.76% | 58.51% | 56.71% | |
Intangible Assets out of Total Assets |
0.05 | 0.05 | 0.05 | 0.05 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.36 | 0.23 | 0.28 | 0.23 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(22.97%) | (13.19%) | (12.89%) | (25.58%) | |
Free Cash Flow Yield |
(52.02%) | (28.24%) | (30.04%) | (7.31%) | |
Revenue per Share |
0.74 | 0.62 | 0.69 | 0.54 | |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Cash per Share |
1.24 | 1.26 | 1.32 | 1.32 | |
Shareholders Equity per Share |
2.30 | 2.31 | 2.36 | 2.50 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.30 | 2.31 | 2.36 | 2.50 | |
Free Cash Flow |
— | — | (43.19) | — | |
Working Capital |
82.09 | 91.06 | 100.18 | 113.46 | |
Capital Expenditures |
— | — | (28.12) | — | |
Net Current Asset Value |
53.33 | 62.72 | 72.04 | 88.15 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.14 | 12.78 | 13.42 | 17.10 | |
Average Inventory |
35.61 | 31.11 | 27.08 | 24.00 | |
Average Assets |
382.37 | 375.37 | 376.80 | 421.10 | |
Average Common Equity |
245.99 | 247.59 | 253.49 | 307.38 |
Columns are period end dates · fundamentals updated 2 Nov 2026